<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Signaling by ERBB2 in Cancer" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Gene amplification of the ERBB2 (HER2) oncogene is observed across various different cancer types. In addition to HER2 gene amplification, sequencing of tumour samples have revealed HER2 mutations, which fall within three major regions:  the extracellular domain (ECD), transmembrane domain/ juxtamembrane domain (TMD/JMD) and kinase domain (KD). Based on the functional studies of their catalytic activity, signaling and drug sensitivity, as well as their time of occurence with respect to treatment, these mutation can be classified as primary mutations, that can be activating or silent, and may confer drug resistance, and secondary mutations, associated with development of drug resistance upon initial response to targeted therapy.&lt;br&gt;&lt;br&gt;Overexpression of ERBB2 (HER2) protein, usually as a consequence of ERBB2 gene amplification, leads to formation of constitutively active, growth factor independent, ERBB2 homodimers, which are sensitive to the therapeutic antibody trastuzumab (herceptin) (Pickl and Ries 2009).&lt;br&gt;Co-overexpression of ERBB2 and its dimerization partner ERBB3 leads to formation of both ERBB2 homodimers and ERRB2:ERBB3 heterodimers and is associated with chemotherapy resistance and reduced relapse-free and overall survival (Spears et al. 2012).&lt;br&gt;&lt;br&gt;Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity (Kancha et al. 2011). Functionally studied ERBB2 KD mutants include ERBB2 L755S, ERBB2 L755P, ERBB2 I767M, ERBB2 D769H, ERBB2 V777L, ERBB2 G778_P780dup, ERBB2 T798I, ERBB2 T798M, ERBB2 V842I, ERBB2 T862A, ERBB2 L869R, ERBB2 H878Y and ERBB2 R896C (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013, Hu, Wan et al. 2015; Hu, Hu et al. 2015, Hanker et al. 2017, Croessmann et al. 2019).&lt;br&gt;&lt;br&gt;Sensitivity to tyrosine kinase inhibitors (TKIs) and the therapeutic antibody trastuzumab (herceptin) differs between different ERBB2 KD mutants (Bose et al. 2013, Rexer et al. 2013, Nagano et al. 2018).&lt;br&gt;&lt;br&gt;ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers (Greulich et al. 2012).&lt;br&gt;&lt;br&gt;Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation (Ou et al. 2017, Pahuja et al. 2018).&lt;br&gt;&lt;br&gt;ERBB2 TMD/JMD mutants differ in their sensitivity to the therapeutic antibody pertuzumab, which blocks ligand-driven heterodimerization of ERBB2 (Pahuja et al. 2018).
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=1227990 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 1227990</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Orlic-Milacic, Marija</Comment>
  <BiopaxRef>a2a</BiopaxRef>
  <BiopaxRef>e36</BiopaxRef>
  <BiopaxRef>a91</BiopaxRef>
  <BiopaxRef>a5d</BiopaxRef>
  <BiopaxRef>afb</BiopaxRef>
  <BiopaxRef>ae7</BiopaxRef>
  <BiopaxRef>e23</BiopaxRef>
  <BiopaxRef>cd7</BiopaxRef>
  <BiopaxRef>a23</BiopaxRef>
  <BiopaxRef>fa9</BiopaxRef>
  <BiopaxRef>dba</BiopaxRef>
  <BiopaxRef>fe4</BiopaxRef>
  <BiopaxRef>a47</BiopaxRef>
  <BiopaxRef>d61</BiopaxRef>
  <BiopaxRef>d15</BiopaxRef>
  <Attribute Key="reactome_id" Value="1227990" />
  <Graphics BoardWidth="486.0" BoardHeight="507.0" />
  <DataNode TextLabel="Constitutive&#xA;Signaling by&#xA;Overexpressed ERBB2" GraphId="f4b54" Type="Pathway">
    <Comment Source="Reactome">Overexpression of ERBB2 (HER2), usually as a consequence of ERBB2 gene amplification, results in formation of ERBB2 homodimers. Under normal conditions, only ERBB2 heterodimers form, as ERBB2 is expressed at low levels.&lt;br&gt;ERBB2 homodimerization leads to activation of ERBB2 signaling in the absence of growth factors. Signaling by ERBB2 homodimers mainly activates the RAS/RAF/MAPK signaling cascade, while PI3K/AKT signaling is not significantly affected (Pickl and Ries 2009).&lt;br&gt;Trastuzumab (Herceptin), a recombinant antibody clinically approved as an anti-cancer therapeutic for ERBB2-overexpressing cancers, preferentially binds to ERBB2 homodimers (Pickl and Ries 2009).&lt;br&gt;Accurate functional analysis of ERBB2 signaling may require 3D instead of 2D cell culture (Pickl and Ries 2009).</Comment>
    <BiopaxRef>a2a</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="287.5" CenterY="95.5" Width="329.0" Height="57.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9634285" />
  </DataNode>
  <DataNode TextLabel="Signaling by ERBB2&#xA;KD Mutants" GraphId="d26b8" Type="Pathway">
    <Comment Source="Reactome">Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity, leading to cellular transformation (Kancha et al. 2011).&lt;br&gt;Only a subset of potential heterodimerization partners has been tested for most ERBB2 KD mutant proteins, so our annotations here are correspondingly limited. ERBB2 L755S and ERBB2 V777L cancer variants were shown to heterodimerize with ERBB3 (HER3) at a higher rate than wild type ERBB2 (Croessmann et al. 2019). Increased activity of ERBB2 L755S, ERBB2 L755P, ERBB2 V777L, ERBB2 D769H, ERBB2 D769Y, ERBB2 V842I, ERBB2 R896C and ERBB2 G778_P780dup in the presence of either EGFR (Kancha et al. 2011, Bose et al. 2013) or ERBB3 (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013) as a heterodimerization partner was also observed. The interplay of ERBB2 G778_P780dup, ERBB2 I767M and ERBB2 R896C with ERBB3 has not been tested. ERBB2 L869R mutant shows increased activity in the presence of ERBB3, which is further augmented in the presence of dimerization-facilitating ERBB3 E928G mutants (Hanker et al. 2017). The interplay of ERBB2 L869R with EGFR has not been tested. Heterodimerization of ERBB2 KD mutants with ERBB4 has not been tested and ERBB4 is a candidate heterodimerization partner for these KD variants.&lt;br&gt;ERBB2 H878Y mutant has ten times higher kinase activity than the wild type ERBB2 (Hu, Wan et al. 2015; Hu, Hu et al. 2015), but its heterodimerization properties have not been studied and it is therefore annotated as a candidate.&lt;br&gt; Ligand requirements have not been studied in the context of heterodimerization of ERBB2 KD mutants, but it is assumed that ligands are required.&lt;br&gt; The signaling properties of ERBB2 L755M (Gonzalez-Alonso et al. 2015), ERBB2 L755W (COSMIC database: Forbes et al. 2017), ERBB2 V777E (Dietz et al. 2017), ERBB2 V777M (Lee et al. 2006, Ross et al. 2016, Zehir et al. 2017), ERBB2 D769N (Tschui et al. 2015), ERBB2 V842E (Siroy et al. 2015), ERBB2 R896H (Cancer Genome Atlas Research Network 2011), ERBB2 L869Q (Lee et al. 2006) and ERBB2 H878R (Trowe et al. 2008, Zehir et al. 2017) have not been experimentally tested, but they are predicted to be pathogenic (COSMIC database: Forbes et al. 2017) and they are annotated as candidates. ERBB2 T733I (Trowe et al. 2008), ERBB2 T798I (Trowe et al. 2008, Hanker et al. 2017) and ERBB2 T798M (Hanker et al. 2017) usually occur as secondary ERBB2 mutations and are responsible for treatment failure. On their own, ERBB2 T733I and ERBB2 T798I appear to be weakly transforming compared with the other ERBB2 KD mutants. As their signaling properties have been poorly studied, ERBB2 T733I, ERBB2 T798I and ERBB2 T798M are annotated as candidates.&lt;br&gt;The binding of ERBB2 KD mutants to ERBIN and the HSP90:CDC37 chaperone:co-chaperone complex has not been tested but is assumed to occur similarly to the wild type ERBB2.&lt;br&gt;Signaling by ERBB2 KD mutants has been organized into subpathways based on the current knowledge of biology of these mutants (heterodimerization, downstream signaling, drug interaction) and on the sequence similarity of their mutations.</Comment>
    <BiopaxRef>fa9</BiopaxRef>
    <BiopaxRef>afb</BiopaxRef>
    <BiopaxRef>b29</BiopaxRef>
    <BiopaxRef>e5e</BiopaxRef>
    <BiopaxRef>ae7</BiopaxRef>
    <BiopaxRef>fcd</BiopaxRef>
    <BiopaxRef>de2</BiopaxRef>
    <BiopaxRef>cf4</BiopaxRef>
    <BiopaxRef>b75</BiopaxRef>
    <BiopaxRef>e55</BiopaxRef>
    <BiopaxRef>ef9</BiopaxRef>
    <BiopaxRef>ad6</BiopaxRef>
    <BiopaxRef>f74</BiopaxRef>
    <BiopaxRef>a79</BiopaxRef>
    <BiopaxRef>a23</BiopaxRef>
    <BiopaxRef>f1b</BiopaxRef>
    <BiopaxRef>cd7</BiopaxRef>
    <BiopaxRef>e23</BiopaxRef>
    <BiopaxRef>a5d</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="289.5" CenterY="164.0" Width="329.0" Height="58.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9664565" />
  </DataNode>
  <DataNode TextLabel="Drug resistance in&#xA;ERBB2 KD mutants" GraphId="ac50b" Type="Pathway">
    <Comment Source="Reactome">ERBB2 kinase domain (KD) mutants vary in their resistance to various tyrosine kinase inhibitors and therapeutic antibody trastuzumab (herceptin).&#xD;
The following ERBB2 KD mutants are resistant to the therapeutic antibody trastuzumab (herceptin):&lt;br&gt;&lt;br&gt;ERBB2 L755P (Nagano et al. 2018);&lt;br&gt;ERBB2 L755S (Nagano et al. 2018);&lt;br&gt;ERBB2 I767M (Bose et al. 2013);&lt;br&gt;ERBB2 D769Y (Nagano et al. 2018);&lt;br&gt;ERBB2 V777L (Nagano et al. 2018);&lt;br&gt;ERBB2 G778_P780dup (Bose et al. 2013, Nagano et al. 2018);&lt;br&gt;ERBB2 T798M (Rexer et al. 2013);&lt;br&gt;ERBB2 V842I (Nagano et al. 2018);&lt;br&gt;ERBB2 T862A (Nagano et al. 2018);&lt;br&gt;ERBB2 L869R (Hanker et al. 2017);&lt;br&gt;&lt;br&gt;For ERBB2 R896C, both resistance (Bose et al. 2013) and sensitivity (Nagano et al. 2018) to trastuzumab have been reported.&lt;br&gt;</Comment>
    <BiopaxRef>d15</BiopaxRef>
    <BiopaxRef>afb</BiopaxRef>
    <BiopaxRef>d61</BiopaxRef>
    <BiopaxRef>a23</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="291.0" CenterY="234.5" Width="328.0" Height="59.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9665230" />
  </DataNode>
  <DataNode TextLabel="Signaling by ERBB2&#xA;ECD mutants" GraphId="bff85" Type="Pathway">
    <Comment Source="Reactome">ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers. The functionally studied ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012) seem to preferntially heterodimerize with EGFR. Heterodimerization of ERBB2 G309E involves formation of disulfide bonds (Greulich et al. 2012). ERBB2 S310F shows stronger activation of downstream signaling than ERBB2 G309A and ERBB2 G309E, and is hyperphosphorylated on tyrosine residues in the C-tail (Greulich et al. 2012), while the C-tail phosphorylation of ERBB2 G309A (Bose et al. 2013) and ERBB2 G309E (Greulich et al. 2012) is comparable to the wild type ERBB2.&lt;br&gt; RAS signaling and PLCgamma1 signaling are activated dowsntream of all three ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012), as evidenced by activating phosphorylation on ERKs (MAPK1 and MAPK3) and PLCG1, respectively. ERBB2 G309E and ERBB2 S310F also activate PI3K/AKT signaling, demonstrated by activating phosphorylation of AKT1 (Greulich et al. 2012). Activation of PI3K/AKT signaling downstream of ERBB2 G309A has not been tested. Signaling downstream of ERBB2 S310Y has been poorly characterized and it is annotated as a candidate. Many regulators of cell migration show increased phosphorylation in cells expressing ERBB2 G309E and ERBB2 S310F (Greulich et al. 2012).&lt;br&gt;Comapred with the wild type ERBB2, ERBB2 G309E, ERBB2 S310F and ERBB2 S310Y are more sensitive to the ERBB2-directed therapeutic antibody trastuzumab (herceptin) and to tyrosine kinase inhibitors lapatinib, neratinib and afatinib (Greulich et al. 2012). ERBB2 G309A was also responsive to trastuzumab, lapatinib and neratinib (Bose et al. 2013).</Comment>
    <BiopaxRef>dba</BiopaxRef>
    <BiopaxRef>afb</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="290.5" CenterY="301.5" Width="329.0" Height="59.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9665348" />
  </DataNode>
  <DataNode TextLabel="Signaling by ERBB2&#xA;TMD/JMD mutants" GraphId="e9700" Type="Pathway">
    <Comment Source="Reactome">Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. The ERBB2 TMD mutants include ERBB2 V659E, ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 S653C, ERBB2 R677L and ERBB2 R678Q. The ERBB2 JMD mutants include ERBB2 E693K and ERBB2 Q709L. ERBB2 TMD mutants  ERBB2 V659E, ERBB2 G660D and S653C (de Martino et al. 2014) are known to be activating. ERBB2 TMD/JMD mutants ERBB2 R678Q, ERBB2 E693K, and ERBB2 Q709L mutations may be activating when co-expressed with a wild type ERBB2 receptor (Pahuja et al. 2018). TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation. TMD/JMD mutants that are activating in the presence of wild type ERBB2, such as ERBB2 R678Q, may form homodimers with the wild type ERBB2 (Pahuja et al. 2018).&lt;br&gt;&lt;br&gt;Based on trans-autophosphorylation of ERBB2 and its dimerization partners EGFR and ERBB3, the following ERBB2 TMD/JMD mutants are assumed to form heterodimers with EGFR and ERBB3:&lt;br&gt;ERBB2 S653C (de Martino et al. 2014)&lt;br&gt;ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018).&lt;br&gt;&lt;br&gt;Phosphorylation of tyrosine residues in the C-tail of ERBB2 was shown for the following ERBB2 TMD/JMD mutants:&lt;br&gt;ERBB2 V659E (Pahuja et al. 2018);&lt;br&gt;ERBB2 V659K (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660D (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660R (Pahuja et al. 2018);&lt;br&gt;ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1248 demonstrated);&lt;br&gt;ERBB2 R677L (Pahuja et al. 2018);&lt;br&gt;ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1248 demonstrated; Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018)&lt;br&gt;&lt;br&gt;Phosphorylation of tyrosine residues in the C-tail of EGFR was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1068) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1068).&lt;br&gt;&lt;br&gt;Phosphorylation of tyrosine residues in the C-tail of ERBB3 was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1197) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1197).&lt;br&gt;&lt;br&gt;Activation of downstream RAS signaling was shown for ERBB2 S653C (de Martino et al. 2014) and ERBB2 R678Q (Bose et al. 2013, de Martino et al. 2014) through activating tyrosine phosphorylation on ERKs (MAPK1 and MAPK3) and SHC1.&lt;br&gt;&lt;br&gt;Activation of downstream PLCG1 signaling was demonstrated for ERBB2 R678Q, through activating tyrosine phosphorylation on PLCG1 (Bose et al. 2013).&lt;br&gt;&lt;br&gt;Activation of PI3K/AKT signaling by ERBB2 TMD/JMD mutants has not been tested.&lt;br&gt;&lt;br&gt;Signaling by ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 R677L, ERBB2 E693K and ERBB2 Q709L has not been sufficiently studied and they are annotated as candidates.&lt;br&gt;&lt;br&gt;The following ERBB2 TMD/JMD mutants are sensitive to  the therapeutic antibody trastuzumab (herceptin):&lt;br&gt;ERBB2 V659E (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660D (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660R (Pahuja et al. 2018);&lt;br&gt;ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018);&lt;br&gt;ERBB2 Q709L (Pahuja et al. 2018);&lt;br&gt;&lt;br&gt;With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).&lt;br&gt;&lt;br&gt;The following ERBB2 TMD/JMD mutants are sensitive to lapatinib:&lt;br&gt;ERBB2 S653C (de Martino et al. 2014);&lt;br&gt;ERBB2 R678Q (Bose et al. 2013);&lt;br&gt;&lt;br&gt;The following ERBB2 TMD/JMD mutants are sensitive to neratinib:&lt;br&gt;ERBB2 V659E (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660D (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660R (Pahuja et al. 2018);&lt;br&gt;ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018);&lt;br&gt;ERBB2 Q709L (Pahuja et al. 2018);&lt;br&gt;&lt;br&gt;The following ERBB2 TMD/JMD mutants are sensitive to afatinib:&lt;br&gt;ERBB2 G660D (Pahuja et al. 2018);&lt;br&gt;ERBB2 G660R (Pahuja et al. 2018);&lt;br&gt;ERBB2 S653C (de Martino et al. 2014);&lt;br&gt;ERBB2 R678Q (Pahuja et al. 2018);&lt;br&gt;ERBB2 Q709L (Pahuja et al. 2018).</Comment>
    <BiopaxRef>afb</BiopaxRef>
    <BiopaxRef>bd2</BiopaxRef>
    <BiopaxRef>fe4</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="290.5" CenterY="373.0" Width="327.0" Height="60.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9665686" />
  </DataNode>
  <DataNode TextLabel="Drug resistance in&#xA;ERBB2 TMD/JMD&#xA;mutants" GraphId="fd02b" Type="Pathway">
    <Comment Source="Reactome">With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).</Comment>
    <BiopaxRef>fe4</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="291.0" CenterY="445.5" Width="330.0" Height="63.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-9665737" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a2a">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18978815</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pickl M, Ries CH.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e36">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27903463</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J, Campregher PV, Ross JS, Stephens PJ, Miller VA, Suh JH, Ali SM, Velcheti V.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a91">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21638049</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Spears M, Taylor KJ, Munro AF, Cunningham CA, Mallon EA, Twelves CJ, Cameron DA, Thomas J, Bartlett JM.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a5d">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22046346</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="afb">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23220880</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Activating HER2 mutations in HER2 gene amplification negative breast cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, Ma CX, Ding L, Mardis ER, Ellis MJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ae7">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23843458</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Collier TS, Diraviyam K, Monsey J, Shen W, Sept D, Bose R.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e23">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25853726</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hu Z, Wan X, Hao R, Zhang H, Li L, Li L, Xie Q, Wang P, Gao Y, Chen S, Wei M, Luan Z, Zhang A, Huang N, Chen L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cd7">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26375550</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hu Z, Hu Y, Liu X, Xi R, Zhang A, Liu D, Xie Q, Chen L.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a23">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28274957</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An Acquired &lt;i&gt;HER2&lt;/i&gt;&lt;sup&gt;T798I&lt;/sup&gt; Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Hanker AB, Brewer MR, Sheehan JH, Koch JP, Sliwoski GR, Nagy R, Lanman R, Berger MF, Hyman DM, Solit DB, He J, Miller V, Cutler RE, Lalani AS, Cross D, Lovly CM, Meiler J, Arteaga CL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fa9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30314968</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Combined Blockade of Activating &lt;i&gt;ERBB2&lt;/i&gt; Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Croessmann S, Formisano L, Kinch LN, Gonzalez-Ericsson PI, Sudhan DR, Nagy RJ, Mathew A, Bernicker EH, Cristofanilli M, He J, Cutler RE, Lalani AS, Miller VA, Lanman RB, Grishin NV, Arteaga CL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="dba">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22908275</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Greulich H, Kaplan B, Mertins P, Chen TH, Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, Liao R, Imielinski M, Banerji S, Berger AH, Lawrence MS, Zhang J, Pho NH, Walker SR, Winckler W, Getz G, Frank D, Hahn WC, Eck MJ, Mani DR, Jaffe JD, Carr SA, Wong KK, Meyerson M.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fe4">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30449325</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, Chaudhuri S, Kljavin NM, Antony A, Phalke S, Kumar P, Mravic M, Stawiski EW, Vargas D, Durinck S, Gupta R, Khanna-Gupta A, Trabucco SE, Sokol ES, Hartmaier RJ, Singh A, Chougule A, Trivedi V, Dutt A, Patil V, Joshi A, Noronha V, Ziai J, Banavali SD, Ramprasad V, DeGrado WF, Bueno R, Jura N, Seshagiri S.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a47">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">31292270</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Emergence of &lt;i&gt;ERBB2&lt;/i&gt; Mutation as a Biomarker and an Actionable Target in Solid Cancers.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Subramanian J, Katta A, Masood A, Vudem DR, Kancha RK.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d61">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">23948973</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Rexer BN, Ghosh R, Narasanna A, Estrada MV, Chakrabarty A, Song Y, Engelman JA, Arteaga CL.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d15">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29967253</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">High-Throughput Functional Evaluation of Variants of Unknown Significance in &lt;i&gt;ERBB2&lt;/i&gt;.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nagano M, Kohsaka S, Ueno T, Kojima S, Saka K, Iwase H, Kawazu M, Mano H.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b29">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26287187</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">González-Alonso P, Chamizo C, Moreno V, Madoz-Gúrpide J, Carvajal N, Daoud L, Zazo S, Martín-Aparicio E, Cristóbal I, Rincón R, García-Foncillas J, Rojo F.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e5e">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27899578</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">COSMIC: somatic cancer genetics at high-resolution.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="fcd">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25809292</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tschui J, Vassella E, Bandi N, Baumgartner U, Genitsch V, Rotzer D, Seiler R, Thalmann GN, Fleischmann A.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="de2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25994018</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, Arnould L, Geyer FC, Bromberg SE, Lacroix-Triki M, Penault-Llorca F, Giard S, Sastre-Garau X, Natrajan R, Norton L, Cottu PH, Weigelt B, Vincent-Salomon A, Reis-Filho JS.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cf4">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">18413839</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Trowe T, Boukouvala S, Calkins K, Cutler RE, Fong R, Funke R, Gendreau SB, Kim YD, Miller N, Woolfrey JR, Vysotskaia V, Yang JP, Gerritsen ME, Matthews DJ, Lamb P, Heuer TS.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="b75">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">29088767</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Dietz S, Sültmann H, Du Y, Reisinger E, Riediger AL, Volckmar AL, Stenzinger A, Schlesner M, Jäger D, Hohenfellner M, Duensing S, Grüllich C, Pahernik S.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="e55">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">27284958</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ef9">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">16397024</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lee JW, Soung YH, Seo SH, Kim SY, Park CH, Wang YP, Park K, Nam SW, Park WS, Kim SH, Lee JY, Yoo NJ, Lee SH.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="ad6">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">28481359</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f74">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">25148578</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a79">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">21720365</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Integrated genomic analyses of ovarian carcinoma.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cancer Genome Atlas Research Network.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f1b">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">30301790</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bd2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">24971884</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

